Abstract
Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cognition- and circuit-based dysfunction in a mouse model of 22q11.2 microdeletion syndrome: effects of stress
Translational Psychiatry Open Access 28 January 2020
-
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
Nature Communications Open Access 08 November 2018
-
Lateral habenula perturbation reduces default-mode network connectivity in a rat model of depression
Translational Psychiatry Open Access 27 March 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Godsil, B. P. et al. The hippocampal−prefrontal pathway: the weak link in psychiatric disorders? Eur. Neuropsychopharmacol. 23, 1165–1181 (2013).
Troyano-Rodríguez, E. et al. Phencyclidine inhibits the activity of thalamic reticular gamma-aminobutyric acidergic neurons in rat brain. Biol. Psychiatry 76, 937–945 (2014).
Santana, N. et al. Activation of thalamocortical networks by the N-methyl-d-aspartate receptor antagonist phencyclidine: reversal by clozapine. Biol. Psychiatry 69, 918–927 (2011).
Lladó-Pelfort, L. et al. Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: effects of antipsychotic drugs and receptor ligands. Eur. Neuropsychopharmacol. 26, 614–625 (2016).
Grimm, O. et al. Acute ketamine challenge increases resting state prefrontal–hippocampal connectivity in both humans and rats. Psychopharmacology 232, 4231–4241 (2015).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Some of the authors are employed in the pharmaceutical industry, as indicated in the address list.
Rights and permissions
About this article
Cite this article
Artigas, F., Schenker, E., Celada, P. et al. Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS. Nat Rev Drug Discov 16, 1–2 (2017). https://doi.org/10.1038/nrd.2016.205
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.205
This article is cited by
-
Drug targeting in psychiatric disorders — how to overcome the loss in translation?
Nature Reviews Drug Discovery (2024)
-
Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology
Psychopharmacology (2021)
-
Cognition- and circuit-based dysfunction in a mouse model of 22q11.2 microdeletion syndrome: effects of stress
Translational Psychiatry (2020)
-
NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in rats
Psychopharmacology (2019)
-
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
Nature Communications (2018)